a
a
Weather:
No weather information available
HomemoviesBooksCardiawave Announces Positive 12-Month Results from Its “Valvosoft® FIM Study” and “Valvosoft® Pivotal Study” for the Treatment of Severe Symptomatic Aortic Stenosis (sSAS)

Cardiawave Announces Positive 12-Month Results from Its “Valvosoft® FIM Study” and “Valvosoft® Pivotal Study” for the Treatment of Severe Symptomatic Aortic Stenosis (sSAS)

At the EuroPCR 2025 Congress -�Paris Results confirm the promise of non-invasive ultrasound therapy (NIUT) previously observed in earlier clinical studies. • 91% of patients were free of major adverse cardiac events (MACE) at 30 days (achieving the primary endpoint objective MACE ≤ 25%). – • 85% of patients experienced an improvement or stabilization in their NYHA class. – • An average 9-point improvement in the KCCQ (Kansas City Cardiomyopathy Questionnaire) score, indicating a…

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=339182

No comments

Sorry, the comment form is closed at this time.

Translate »